📊 IMNM Key Takeaways
Is Immunome Inc. (IMNM) a Good Investment?
Immunome is a pre-revenue pharmaceutical company burning approximately $58.6M annually in operating losses with zero commercial revenue. While the balance sheet is fortress-like with $582.7M cash and minimal debt ($500K), the company remains entirely unprofitable with negative free cash flow of -$61.6M, demonstrating no demonstrated commercial viability or revenue-generating capability as of Q1 2026.
Immunome’s balance sheet is very strong, with ~$653M in cash, minimal debt, and a ~14.7x current ratio that supports a multi‑year runway. However, fundamentals are weak: revenue is small and declining, margins are deeply negative, and free cash flow is heavily negative, indicating no near‑term path to profitability. On fundamentals alone, the robust liquidity offsets solvency risk but not the execution and commercialization risks.
Immunome Inc. Key Strengths (IMNM)
- Fortress balance sheet with $582.7M cash and only $500K long-term debt
- Exceptional liquidity ratios (21.68x current ratio) ensuring 10+ year cash runway at current burn rates
- Minimal leverage (0.00 debt/equity) and no significant debt burden
- Improving diluted EPS trend (+51.4% YoY, though still -$0.48)
- Exceptional liquidity and cash runway (~$653M cash)
- Minimal leverage and strong equity base
- Large asset base relative to low liabilities
IMNM Stock Risks: Immunome Inc. Investment Risks
- Zero revenue as of latest period - completely pre-revenue with no commercial products
- Substantial annual cash burn of $58.6M from operations without offsetting revenue
- Negative operating income of -$59.3M and negative free cash flow of -$61.6M
- Entire value dependent on successful drug development and FDA approval in competitive pharma sector
- High execution risk typical of clinical-stage biotech with no revenue visibility
- Sustained high cash burn and deeply negative FCF
- Declining revenue with no clear gross margin/commercial traction
- Potential future dilution/financing needs once runway shortens
Key Metrics to Watch
- Clinical trial milestones and pipeline advancement status
- Monthly cash burn rate and any changes to operating burn
- Time to potential revenue generation and commercialization timeline
- Capital raise announcements and additional financing needs
- R&D spending efficiency and whether burn rate accelerates or decelerates
- Operating cash flow (quarterly burn rate)
- R&D + G&A expense trend
Immunome Inc. (IMNM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 21.68x current ratio provides a solid financial cushion.
IMNM Profit Margin, ROE & Profitability Analysis
IMNM vs Healthcare Sector: How Immunome Inc. Compares
How Immunome Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immunome Inc. Stock Overvalued? IMNM Valuation Analysis 2026
Based on fundamental analysis, Immunome Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immunome Inc. Balance Sheet: IMNM Debt, Cash & Liquidity
IMNM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immunome Inc.'s revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-5.00 indicates the company is currently unprofitable.
IMNM Revenue Growth, EPS Growth & YoY Performance
IMNM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$41.6M | $-0.48 |
| Q3 2025 | N/A | -$36.1M | $-0.65 |
| Q2 2025 | $2.4M | -$36.1M | $-0.50 |
| Q1 2025 | $1.0M | -$41.6M | $-0.52 |
| Q3 2024 | $2.9M | -$4.3M | $-0.36 |
| Q2 2024 | $2.4M | -$4.3M | $-0.46 |
| Q1 2024 | $1.0M | -$4.3M | $-0.35 |
| Q3 2023 | $3.6M | -$4.3M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immunome Inc. Dividends, Buybacks & Capital Allocation
IMNM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immunome Inc. (CIK: 0001472012)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMNM
What is the AI rating for IMNM?
Immunome Inc. (IMNM) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMNM's key strengths?
Claude: Fortress balance sheet with $582.7M cash and only $500K long-term debt. Exceptional liquidity ratios (21.68x current ratio) ensuring 10+ year cash runway at current burn rates. ChatGPT: Exceptional liquidity and cash runway (~$653M cash). Minimal leverage and strong equity base.
What are the risks of investing in IMNM?
Claude: Zero revenue as of latest period - completely pre-revenue with no commercial products. Substantial annual cash burn of $58.6M from operations without offsetting revenue. ChatGPT: Sustained high cash burn and deeply negative FCF. Declining revenue with no clear gross margin/commercial traction.
What is IMNM's revenue and growth?
Immunome Inc. reported revenue of $0.0.
Does IMNM pay dividends?
Immunome Inc. does not currently pay dividends.
Where can I find IMNM SEC filings?
Official SEC filings for Immunome Inc. (CIK: 0001472012) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMNM's EPS?
Immunome Inc. has a diluted EPS of $-0.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IMNM's fundamental grade?
Based on our AI fundamental analysis in May 2026, Immunome Inc. has a C grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IMNM stock overvalued or undervalued?
Valuation metrics for IMNM: ROE of -9.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IMNM's AI grade for 2026?
Our dual AI analysis gives Immunome Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMNM's free cash flow?
Immunome Inc.'s operating cash flow is $-58.6M, with capital expenditures of $3.0M.
How does IMNM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -9.1% (avg: 15%), current ratio 21.68 (avg: 2).